Pfizer Reports Q3 2026 Results with Increased Full-Year Guidance Amid Non-COVID Growth
Pfizer (PFE) reported third-quarter revenue of $16.6 billion, which remained relatively flat year-over-year as a 7% growth in non-COVID products was offset by declining sales from Paxlovid and Comirnaty. Despite the impact of lower COVID-19 product demand, the company raised its full-year 2026 revenue guidance to a range of $62 billion to $64 billion, citing strong commercial momentum. The company's non-COVID portfolio showed significant strength, particularly in oncology and specialty medicines. Key drivers included Padcev, which grew 55% operationally, and Eliquis, which saw a 25% increase driven by higher U.S. net prices. Pfizer also remains on track to meet its $7.2 billion cost-savings target while increasing R&D investment to support obesity and oncology clinical programs.
Tickers: $PFE
Topics: EPS Guidance Pharmaceuticals Revenue